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Abstract: Endomyocardial biopsy (EMB) is useful for the diagnosis of myocarditis, cardiac sarcoidosis, and non-
ischemic cardiomyopathy. In this mini-review, we discuss the diagnostic potential of EMB in cases of acute/chronic-
active myocarditis, sarcoidosis, idiopathic dilated cardiomyopathy and arrhythmogenic right ventricular dysplasia. 
We also summarize the complications caused by endomyocardial biopsy procedures. Importantly, we finally review 
the emerging molecular biology technologies as well as biological engineering techniques that can help improve the 
diagnostic accuracy of EMB to diagnose myocarditis and cardiomyopathies, promoting the management of these 
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Introduction
Endomyocardial biopsy (EMB) is useful to es- 
tablish a definite diagnosis of myocarditis, car-
diac sarcoidosis, and non-ischemic cardiomy-
opathies [1-3]. The clinical and physiopatho- 
logical relevance of biopsy-based diagnosis of 
myocarditis, cardiac sarcoidosis, and unexpla- 
ined cardiomyopathies has been highlighted 
by several reports demonstrating the potential 
of EMB-based causal treatment strategies (im- 
munosuppressive or antiviral therapies) and 
the advantage of EMB-based exploration of 
the etiology of cardiomyopathies. This is espe-
cially true when using EMB in combination with 
emerging molecular biology technologies, bio-
logical engineering techniques, and imaging 
tools such as cardiac magnetic resonance to- 
mography (CMR) and positron emission tomog-
raphy (PET) which can significantly improve the 
diagnostic accuracy for myocarditis, cardiac 
sarcoidosis, cardiomyopathies, or other diseas-
es [4-10].
Because EMB is an invasive strategy with a 
potential risk of complications such as cardiac 
tamponade/pericardial effusion, pericardiocen-
tesis, ventricular arrhythmias or complete atrio-
ventricular block, its clinical use should only be 
practiced by experienced interventionalists 
who are following a strict protocol. This protocol 
includes several echocardiographic examina-
tions before, immediately after, and one hour 
later to detect relevant hemopericardium that 
can be treated by regular pericardiocentesis. In 
case of continuous bleeding, a catheter can be 
left in place until the bleeding stops, which can 
sometimes be achieved even after two to three 
days. In the most severe situation, connection 
of the catheter inside the pericardial space to a 
mechanical autotransfusion system (e.g. Cell 
Saver®) or even electric pump can reinject the 
blood in the patient́ s circulation. With these 
techniques, continuing tamponade requiring 
surgical intervention has been very rare. 
EMB in acute myocarditis
In acute myocarditis, EMB is indicated when 
classical clinical signs associated with a signifi-
cant decrease of LVEF with or without arrhyth-
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mias occur within 48 hours after the time of 
hospitalization [1, 3, 9, 11] because superim-
posed myocarditis in some patients with car-
diomyopathies can lead to rapid disease pro-
gression eventually necessitating cardiac re- 
placement therapy (Figure 1) [12, 13]. In such 
case, therefore, an early EMB is indicated and 
allows one to characterize and quantitate the 
presence of an inflammatory infiltrate with or 
without cardiomyocyte necrosis using classical 
cated in cases of acute symptoms of heart fail-
ure refractory to traditional strategies [4, 14, 
15]. Histological and immunohistological exam-
ination of EMB tissue allows to confirm the clini-
cal and imaging based diagnosis by the detec-
tion of interstitial fibrosis associated with the 
absence of inflammatory infiltrates, allowing to 
rule out an acute or a chronic-active form of 
myocarditis [8]. Various common viral genomes 
could be amplified in EMBs from IDCM patients. 
Figure 1. A: A 28-year-old male patient in whom the clinical course was il-
lustrated by release of troponin and progressive decrease in left ventricular 
ejection fraction (LVEF), and finally heart transplant confirming the diagnosis 
of ARVD, but also showing a typical involvement of both ventricles by histo-
logical signs of lymphocytic myocarditis. A zone of chronic-active myocarditis 
in the LV in the same case indicated major loss of cardiac function leading 
to progressive deterioration of heart function and transplantation. (With per-
mission from Ardan Saguner [12]). B: Role of superimposed myocarditis on 
deterioration of LVEF during follow-up in patients with ARVD and IDCM. This 
explains the wide spectrum of clinical evolution of heart failure well known in 
IDCM (With permission from Guy Fontaine [27]).
histological and immunohisto-
logical techniques [1, 4, 11]. 
Moreover, available molecular 
techniques can allow a rapid 
simultaneous and reliable de- 
tection of cardiotropic viruses 
in EMB samples. This allows 
distinction of an auto-immune 
from a viral myocarditis, and 
therefore avoids the use of 
corticosteroids and immuno-
suppressive drugs in cases of 
ongoing viral cardiac infection 
[4]. When myocarditis is pres-
ent, both ventricles can be 
affected in the same way. 
Therefore, EMB can be per-
formed either on the right or 
the left ventricle free wall as 
well as in the right or left wall 
of the septum. Because of the 
well-known multifocal nature 
of myocarditis, 7-9 biopsy 
samples should be performed 
in both ventricles if the first 
biopsy taken from the right-
sided septum is negative. Ce- 
rebral protection devices dur-
ing left-sided biopsy can help 
to prevent procedure-related 
TIA/stroke (e.g. TriGUARD3™). 
In virologically well-identified 
infectious myocarditis pre-
venting direct viral damage 
using specific antiviral thera-
py becomes one possible 
approach in clinical trials or in 
temporary authorized use of 
drugs [1, 4, 9, 14].
EMB in idiopathic dilated car-
diomyopathy
In idiopathic dilated cardiomy-
opathy (IDCM), EMB is indi-
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The presence of two or even three viruses in 
the same patient are markers of poor outcome 
[15, 16]. Cardiac viral infections could trigger or 
contribute as co-factors to the development of 
the disease in a large fraction of IDCM patients. 
Some viral infections in IDCM patients could 
predict a bad long-term prognosis. Altogether 
this evidence supports the concept of the exis-
tence of a subset of viral-infection based DCM 
among IDCM patients [1]. In IDCM patients, the 
molecular identification of viral cardiotropic 
agents and the assessment of viral load levels 
could be of major interest to establish a prog-
nostic marker of heart failure evolution, and 
therefore to improve monitoring and therapeu-
tic management. Currently, the progress of 
molecular biology leads to rapid and accurate 
viral detection in EMB, especially in patients 
admitted to the hospital due to unexplained 
heart failure such as individuals with IDCM. 
Practically, these emerging biotechnologies 
have positive effects in promoting the  manage-
ment of patients with IDCM, but also to evalu-
ate the impact of common human cardiotropic 
viruses such as enteroviruses, HHV6 and par-
vovirus B19 in DCM [5, 7, 8, 10]. Notably, in 
some cases of IDCM, there can also be the 
completely healed form where one sees hyaline 
fibrosis with no lymphocytes.
EMB in arrhythmogenic right ventricular dys-
plasia
Arrhythmogenic right ventricular dysplasia 
(ARVD) was recognized in 1977 during antiar-
tricle, leading to congestive heart failure and 
death [14, 19-23]. In ARVD cases, EMB is not 
routinely indicated because the diagnosis is 
based on the association of arrhythmias, spe-
cific ECG features, cardiac echocardiographic 
abnormalities, cardiac magnetic resonance im- 
aging, RV angiography, and family history and 
genetic testing [21]. The severe progression in 
ARVD could be also the result of co-factors 
related to the environment as common cardio-
tropic viruses or bacteria. Some published 
cases have demonstrated in ARVD patients the 
presence of an active myocarditis “superim-
posed” on the genetic background of ARVD [12, 
13, 24, 25]. This phenomenon of a superim-
posed inflammatory process can explain the 
wide spectrum of disease progression in ARVD, 
which could be related to the susceptibility of 
the patient for a particular virus and the kind of 
virus involved in this co-factor of morbidity. 
Further prospective clinical studies on ARVD 
should include EMB sampling to explore the 
pathophysiological mechanisms and more spe-
cifically the presence of myocardial infection 
by common cardiotropic viruses. In order to 
secure EMB sampling and to exclude patients 
with a potentially increased risk of perforation 
during EMB, CMR, PET or 3D electroanatomical 
voltage mapping can be used to localize the 
substrate in order to increase the diagnostic 
yield, and also to avoid EMB from unaffected 
regions or thin fibro-fatty areas in the RV myo-
cardium that are particularly prone to per- 
foration. 
Figure 2. Typical pathology findings in arrhythmogenic ventricular cardiomy-
opathy/dysplasia (ARVC/D). A: Macroscopic finding in a patient with arrhyth-
mogenic right ventricular cardiomyopathy/dysplasia. The myocardium of the 
right ventricular free wall is partially replaced by fibro-fatty tissue (black ar-
row) that typically begins in the epicardial region and at later stages expands 
transmurally; B: Endomyocardial biopsy from a patient with ARVC/D demon-
strating fatty (black arrow) replacement of the right ventricular myocardium. 
Strands of myocardium are still visible (White arrow, heidenhain trichrome, 
magnification × 60). (With permission from Ardan Saguner [23]).
rhythmic surgery in Pitié Sal- 
pêtrière Hospital (Paris, Fran- 
ce) [17]. The dysplasia pre-
dominantly involved the origi-
nal right ventricular “triangle 
of dysplasia”. The diagnosis 
of ARVD was pathologically 
based on our previous find-
ings of myocardium embed-
ded in or bordered by fatty 
tissue and/or fibrosis (Figure 
2) [17, 18]. Biventricular in- 
volvement is very frequently 
observed at later stages 
(Figure 3A); surviving cardio-
myocytes (Figure 3B) and 
zones of fibrosis (Figure 3C) 
are observed in the same 
patient on the right as well as 
external part of the left ven-
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Conclusions
EMB is still regarded as the gold standard to 
establish the diagnosis of some cardiovascular 
diseases, which are difficult to diagnose by 
noninvasive testing. Moreover, histopathologi-
cal, immunological and virological information 
provided by analyses of EMB samples are of 
major interest to evaluate present or future 
causal treatment strategies (immunosuppres-
sive or antiviral therapies), and to explore the 
pathophysiological mechanisms of etiologically 
unknown cardiomyopathies [15, 16, 26]. The 
new reliable and safe CMR and PET scan proto-
cols used in the diagnosis of myocarditis, car-
diac sarcoidosis, or unexplained cardiomyopa-
thies remain to be prospectively validated 
against classical EMB procedures, allowing the 
characterization of myocardial lesions and in- 
flammatory processes induced directly by ex- 
ogenous factors (toxins, drugs, viruses, bacte-
ria, parasites) or indirectly by autoimmune me- 
chanisms.
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